Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with
varying degrees of dysplasia and peripheral cytopenias. MDS are driven by structural …

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem
cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates …

Myelodysplastic neoplasms (MDS) form a broad spectrum of clonal myeloid malignancies
arising from hematopoietic stem cells that are characterized by progressive and refractory …

Single-agent hypomethylating agents remain the cornerstone of treatment for patients with
high-risk myelodysplastic syndromes. Although these agents have clinical activity and can …

Accurate risk prognostication is central to the management of myelodysplastic syndromes,
given the widely heterogeneous clinical outcomes of these bone marrow failure disorders …

Risk stratification is crucial to the appropriate management of most cancers, but in patients
with myelodysplastic syndromes (MDS), for whom expected survival can vary from a few …

Simple Summary The revised international prognostic scoring system (IPSS-R) represents
the standard tool for prognostication in myelodysplastic syndromes (MDSs). It considers the …